Multiple Sclerosis Drugs Market by Drug Class (Immunosuppressants, Interferon, Others)
The Global Multiple Sclerosis Drugs Market size is expected to grow from USD 28.83 billion in 2022 to USD 41.95 billion by 2030, at a CAGR of 4.8% during the forecast period (2023-2030).
Multiple sclerosis (MS) is a chronic neurological disease caused by an unknown inflammatory process in the central nervous system (CNS), resulting in multifocal demyelination and axonal loss primarily in the white matter but also in the grey matter of both the brain and the spinal cord. Clinical manifestations vary depending on the anatomical location of inflammatory lesions and are expressions of acute demyelination, which can resolve completely or partially chronic demyelination, and neuroaxonal injury, which is generally irreversible, or both.